Cheryl Cohen, serving as a director at ImmunityBio, Inc. (NASDAQ:IBRX), executed a series of transactions in the company's equity on July 2, 2026. The actions included the sale of common stock and the acquisition of additional shares through option exercises. The sales were processed at prices ranging between $9.50 and $9.52 per share, resulting in a total realized value of $1,246,941 from the disposition of 131,210 shares. These sales were executed under the parameters of a Rule 10b5-1 trading plan that was initially established on February 27, 2026.
Concurrently with the sales, Ms. Cohen acquired 55,979 shares of ImmunityBio common stock through the exercise of stock options. The exercise price for these options was set at $2.98 per share, translating to a total transaction value of $166,817. Following the completion of these transactions, Ms. Cohen's direct holdings in ImmunityBio common stock stood at 125,386 shares.
The insider activity occurs against a backdrop of substantial price movement for the company's shares. The stock has experienced a 227% appreciation over the trailing twelve months. Technical indicators from InvestingPro Tips suggest that the stock's Relative Strength Index (RSI) places it in overbought territory, highlighting the rapid pace of the recent price action. The company currently carries a market capitalization of $9.33 billion. Analyst price targets for the equity are positioned between $12 and $15.
Corporate developments at ImmunityBio have included the presentation of clinical data at major industry conferences. The company shared results from two Phase 3 trials and a comparative study involving its immunotherapy product, ANKTIVA, at the American Society of Clinical Oncology Annual Meeting. Additionally, ImmunityBio presented a health economic analysis at the International Society for Pharmacoeconomics and Outcomes Research conference. This analysis compared the combination of ANKTIVA plus Bacillus Calmette-Guérin against TAR-200 for the treatment of bladder cancer. The company also shared survey data regarding patient treatment preferences for bladder cancer at the same conference, a project conducted in collaboration with the UK-based patient advocacy group, Fight Bladder Cancer.
Regulatory progress remains a focal point for the biotech firm. ImmunityBio announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application for ANKTIVA. The application seeks to expand the indication for ANKTIVA in combination with Bacillus Calmette-Guérin for the treatment of bladder cancer. The FDA's review will focus on the scientific data supporting this expansion, with a target action date set for January 6, 2027.
The recent stock activity by an insider coincides with the company's ongoing efforts to advance its cancer treatment portfolio and navigate the regulatory approval process for its key immunotherapy candidate.